Logo

ORGO

Organogenesis Holdings Inc.

ORGO

Organogenesis Holdings Inc. • NASDAQ
$5.18 ▼ -4.43% (-0.24)
Market Cap $657.40 M
52w High $7.08
52w Low $2.61
Dividend Yield 0%
P/E -64.75
Volume 330.07K
Outstanding Shares 126.91M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $150.864M ▲ $93.886M ▲ $21.567M ▲ 14.296% ▲ $0.11 ▲ $27.26M ▲
Q2-2025 $100.779M ▲ $85.725M ▼ $-9.392M ▲ -9.319% ▲ $-0.096 ▲ $-6.255M ▲
Q1-2025 $86.693M ▼ $89.716M ▲ $-18.843M ▼ -21.735% ▼ $-0.17 ▼ $-15.893M ▼
Q4-2024 $126.656M ▲ $85.386M ▲ $7.673M ▼ 6.058% ▼ $0.059 ▼ $14.641M ▲
Q3-2024 $115.177M $82.139M $12.331M 10.706% $0.093 $10.698M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $64.372M ▼ $509.827M ▲ $123.848M ▲ $385.979M ▲
Q2-2025 $73.076M ▼ $461.128M ▼ $99.909M ▲ $361.219M ▼
Q1-2025 $109.965M ▼ $467.394M ▼ $99.325M ▼ $368.069M ▼
Q4-2024 $135.571M ▲ $497.886M ▲ $112.57M ▼ $385.316M ▲
Q3-2024 $94.34M $446.296M $167.749M $278.547M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $21.567M ▲ $3.079M ▲ $-2.235M ▲ $-10.207M ▼ $-9.363M ▲ $844K ▲
Q2-2025 $-9.392M ▲ $-32.873M ▼ $-3.638M ▼ $-288K ▲ $-36.799M ▼ $-36.511M ▼
Q1-2025 $-18.843M ▼ $-19.935M ▼ $-3.626M ▼ $-2.056M ▼ $-25.617M ▼ $-23.561M ▼
Q4-2024 $7.673M ▼ $10.937M ▲ $-3.361M ▼ $33.649M ▲ $41.225M ▲ $7.576M ▲
Q3-2024 $12.331M $8.695M $-2.569M $-1.677M $4.449M $6.126M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Grant
Grant
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $0 ▲$0 ▲$100.00M ▲$150.00M ▲
Advanced Wound care
Advanced Wound care
 $240.00M ▲$80.00M ▼$0 ▼$0 ▲
Surgical and Sports Medicine
Surgical and Sports Medicine
 $20.00M ▲$10.00M ▼$0 ▼$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has trended upward over the past five years and is now modestly higher than pre‑pandemic levels, showing that demand for the company’s products is generally growing. Gross profitability is solid, suggesting the core products are priced well relative to their production costs. The main challenge is further down the income statement: operating profit has shrunk back toward break‑even in the most recent year after stronger profitability a few years ago. Net income and earnings per share have become very small and volatile, which indicates that even modest changes in pricing, reimbursement, or costs can swing results between a small profit and a small loss.

Balance Sheet

Balance Sheet The balance sheet looks relatively conservative for a smaller healthcare company. Total assets and cash have gradually increased, equity has grown steadily, and debt has come down meaningfully compared with a few years ago. This combination points to a business that has been slowly strengthening its financial base and relying less on borrowing. Overall, the company appears to have a reasonable financial cushion to support operations and growth plans, though not an unusually large one.

Cash Flow

Cash Flow The business consistently generates cash from its operations, but only in modest amounts, and free cash flow tends to hover around breakeven after investment in facilities and equipment. The pattern suggests the company is largely funding itself from internal cash generation while still reinvesting for growth, especially in manufacturing capacity. However, there is not a large cash flow surplus, so major setbacks in sales or margins could quickly tighten liquidity unless spending is adjusted.

Competitive Edge

Competitive Edge Organogenesis occupies a focused niche in advanced wound care and regenerative medicine, with branded products that are well known among specialists. Its living cell therapies and advanced amniotic tissue products, backed by stringent FDA approvals, create meaningful regulatory and scientific barriers for would‑be competitors. The company also benefits from an established sales infrastructure and long‑standing relationships with wound care centers. At the same time, it faces intense competition from other regenerative and wound care players, ongoing scientific debate over comparative effectiveness, and reimbursement pressures, all of which can influence both market share and pricing power.

Innovation and R&D

Innovation and R&D Innovation is a central part of the story. The company’s portfolio spans living cell therapies, amniotic tissue products, and antimicrobial collagen matrices, giving it multiple technological angles in wound healing. It is also working on new indications and products, such as therapies for knee osteoarthritis, burn treatments like the planned reintroduction of TransCyte, and a new biosynthetic wound product. Not every project is straightforward—the missed primary endpoint in a key osteoarthritis trial shows the regulatory and clinical risk in the pipeline. Still, ongoing product development, clinical studies, and manufacturing expansion underline a clear commitment to long‑term R&D‑driven growth.

Summary

Organogenesis combines a specialized, innovation‑heavy business in regenerative medicine with a balance sheet that has been gradually de‑risked and a cash flow profile that is positive but thin. The company’s main strengths lie in its differentiated technologies, strong regulatory positioning, and established commercial network in advanced wound care. Its main vulnerabilities are narrow margins, lumpy profitability, and a highly competitive and regulated environment where clinical data and reimbursement rules can rapidly shift the landscape. Future performance will hinge on its ability to widen margins on its existing products, successfully bring new therapies and burn‑care solutions to market, and maintain its scientific edge against sizeable, well‑funded competitors.

NEWS

November 6, 2025 · 4:05 PM UTC

Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

Read more

November 3, 2025 · 1:10 PM UTC

Organogenesis Applauds CMS's Significant Step In Payment Reform

Read more

October 31, 2025 · 4:05 PM UTC

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

October 28, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

Read more

October 23, 2025 · 10:00 AM UTC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO

Read more